• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    11/14/24 5:49:56 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ORKA alert in real time by email
    SC 13G/A 1 tm2428137d13_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. 1)*

     

    Oruka Therapeutics, Inc. 

    (Name of Issuer)

     

    Common stock, $0.001 par value per share 

    (Title of Class of Securities)

     

    687604108 

    (CUSIP Number)

     

    September 30, 2024 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

     

    x

     

    ¨

    Rule 13d-1(b)

     

    Rule 13d-1(c)

     

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 687604108  Page 2 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨ 

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,541,941 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,541,941 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,541,941 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 668,656 shares and 79,502 shares issuable upon the exercise of immediately exercisable warrants (“Warrants”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 66,890 shares and 9,742 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,350,074 shares and 367,077 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 34,998,550 shares of the Issuer’s Common Stock outstanding as of September 13, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 13, 2024; and (ii) 456,321 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 687604108  Page 3 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨ 

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,541,941 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,541,941 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,541,941 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 668,656 shares and 79,502 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 66,890 shares and 9,742 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,350,074 shares and 367,077 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 34,998,550 shares of the Issuer’s Common Stock outstanding as of September 13, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 13, 2024; and (ii) 456,321 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 687604108  Page 4 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨ 

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,541,941 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,541,941 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,541,941 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 668,656 shares and 79,502 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 66,890 shares and 9,742 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,350,074 shares and 367,077 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 34,998,550 shares of the Issuer’s Common Stock outstanding as of September 13, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 13, 2024; and (ii) 456,321 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 687604108  Page 5 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨ 

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,541,941 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,541,941 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,541,941 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 668,656 shares and 79,502 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 66,890 shares and 9,742 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,350,074 shares and 367,077 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 34,998,550 shares of the Issuer’s Common Stock outstanding as of September 13, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 13, 2024; and (ii) 456,321 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 687604108  Page 6 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨ 

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,541,941 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,541,941 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,541,941 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 668,656 shares and 79,502 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 66,890 shares and 9,742 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,350,074 shares and 367,077 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 34,998,550 shares of the Issuer’s Common Stock outstanding as of September 13, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 13, 2024; and (ii) 456,321 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 687604108  Page 7 of 14

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨ 

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,541,941 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,541,941 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,541,941 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 668,656 shares and 79,502 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 66,890 shares and 9,742 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,350,074 shares and 367,077 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 34,998,550 shares of the Issuer’s Common Stock outstanding as of September 13, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 13, 2024; and (ii) 456,321 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 687604108  Page 8 of 14

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)     (b) ¨ 

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,541,941 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,541,941 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,541,941 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 668,656 shares and 79,502 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 66,890 shares and 9,742 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,350,074 shares and 367,077 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 34,998,550 shares of the Issuer’s Common Stock outstanding as of September 13, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 13, 2024; and (ii) 456,321 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 687604108  Page 9 of 14

     

    Introductory Note:  This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Oruka Therapeutics, Inc. (f/k/a ARCA biopharma, Inc.).

     

    Item 1.
      (a)

    Name of Issuer

     

    Oruka Therapeutics, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    885 Oak Grove Avenue, Suite 100

    Menlo Park, CA 94025

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh 

         
      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.001 par value

         
      (e)

    CUSIP Number

     

    687604108

     

     

     

     

    CUSIP No. 687604108  Page 10 of 14

     

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable
     
    Item 4. Ownership
      (a) Amount beneficially owned as of September 30, 2024:

     

      Venrock Healthcare Capital Partners III, L.P.   3,541,941  (1)
      VHCP Co-Investment Holdings III, LLC   3,541,941  (1)
      Venrock Healthcare Capital Partners EG, L.P.   3,541,941  (1)
      VHCP Management III, LLC   3,541,941  (1)
      VHCP Management EG, LLC   3,541,941  (1)
      Nimish Shah   3,541,941  (1)
      Bong Koh   3,541,941  (1)

     

      (b) Percent of class as of September 30, 2024:

     

      Venrock Healthcare Capital Partners III, L.P.   9.99 % (2)
      VHCP Co-Investment Holdings III, LLC   9.99 % (2)
      Venrock Healthcare Capital Partners EG, L.P.   9.99 % (2)
      VHCP Management III, LLC   9.99 % (2)
      VHCP Management EG, LLC   9.99 % (2)
      Nimish Shah   9.99 % (2)
      Bong Koh   9.99 % (2)

     

      (c) Number of shares as to which the person has, as of September 30, 2024:
        (i) Sole power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   0 
      VHCP Co-Investment Holdings III, LLC   0 
      Venrock Healthcare Capital Partners EG, L.P.   0 
      VHCP Management III, LLC   0 
      VHCP Management EG, LLC   0 
      Nimish Shah   0 
      Bong Koh   0 

     

     

     

     

    CUSIP No. 687604108  Page 11 of 14

     

        (ii) Shared power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   3,541,941  (1)
      VHCP Co-Investment Holdings III, LLC   3,541,941  (1)
      Venrock Healthcare Capital Partners EG, L.P.   3,541,941  (1)
      VHCP Management III, LLC   3,541,941  (1)
      VHCP Management EG, LLC   3,541,941  (1)
      Nimish Shah   3,541,941  (1)
      Bong Koh   3,541,941  (1)

     

        (iii) Sole power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   0 
      VHCP Co-Investment Holdings III, LLC   0 
      Venrock Healthcare Capital Partners EG, L.P.   0 
      VHCP Management III, LLC   0 
      VHCP Management EG, LLC   0 
      Nimish Shah   0 
      Bong Koh   0 

     

        (iv) Shared power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   3,541,941  (1)
      VHCP Co-Investment Holdings III, LLC   3,541,941  (1)
      Venrock Healthcare Capital Partners EG, L.P.   3,541,941  (1)
      VHCP Management III, LLC   3,541,941  (1)
      VHCP Management EG, LLC   3,541,941  (1)
      Nimish Shah   3,541,941  (1)
      Bong Koh   3,541,941  (1)

      

     

     

     

    CUSIP No. 687604108  Page 12 of 14

     

    (1)Consists of (i) 668,656 shares and 79,502 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 66,890 shares and 9,742 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,350,074 shares and 367,077 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2)This percentage is calculated based upon the sum of (i) 34,998,550 shares of the Issuer’s Common Stock outstanding as of September 13, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 13, 2024; and (ii) 456,321 shares issuable upon the exercise of the Warrants described in Footnote 1 above.

     

    Item 5. Ownership of Five Percent or Less of a Class
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
      Not applicable
     
    Item 9. Notice of Dissolution of Group
      Not applicable
     
    Item 10. Certification
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 687604108  Page 13 of 14

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 687604108  Page 14 of 14

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on April 29, 2024)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed April 29, 2024)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on April 29, 2024)

     

     

     

    Get the next $ORKA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORKA

    DatePrice TargetRatingAnalyst
    12/18/2025$75.00Overweight
    Piper Sandler
    11/13/2025$45.00Buy
    Jefferies
    10/27/2025$60.00Buy
    Guggenheim
    10/13/2025$48.00Overweight
    Barclays
    5/22/2025$44.00Buy
    BTIG Research
    2/4/2025$20.00Outperform
    Wolfe Research
    10/11/2024$49.00Buy
    Stifel
    10/7/2024$45.00Buy
    H.C. Wainwright
    More analyst ratings

    $ORKA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,407,368 worth of shares (122,882 units at $11.45) (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    2/27/25 6:42:49 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oruka Therapeutics to Participate in Multiple Upcoming Conferences

    MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Date: Thursday, February 12th, 2026Presentation Time: 10:30AM ET TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3rd, 2026Presentation Time: 1:10PM ET UBS Biotech Summit MiamiDate: Monday March 9th, 2026 Jefferies Biotech on the Beach SummitDate: March 10th, 2026 Leerink

    2/9/26 7:00:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

    ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027 MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announc

    1/12/26 7:00:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026. Presentation DetailsDate: Thursday, January 15th, 2026Time: 9:00 AM PT A webcast and replay of Oruka's presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About Oruka Therapeutics Oruka

    1/6/26 7:00:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Oruka Therapeutics with a new price target

    Piper Sandler initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $75.00

    12/18/25 9:11:03 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Jefferies initiated coverage on Oruka Therapeutics with a new price target

    Jefferies initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00

    11/13/25 9:15:29 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Oruka Therapeutics with a new price target

    Guggenheim initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $60.00

    10/27/25 8:48:30 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Goncalves Joana was granted 32,500 shares, increasing direct ownership by 2,141% to 34,018 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    1/23/26 5:40:40 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Operating Officer Sandler Laura Lee was granted 32,500 shares, increasing direct ownership by 16% to 237,584 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    1/23/26 5:40:21 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SVP, Finance Agarwal Arjun was granted 17,500 shares, increasing direct ownership by 995% to 19,258 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    1/23/26 5:40:03 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.

    SCHEDULE 13G - Oruka Therapeutics, Inc. (0000907654) (Subject)

    1/30/26 2:20:43 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 144 filed by Oruka Therapeutics Inc.

    144 - Oruka Therapeutics, Inc. (0000907654) (Subject)

    12/19/25 4:20:32 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

    12/11/25 4:10:55 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Leadership Updates

    Live Leadership Updates

    View All

    Oruka Therapeutics Announces New Board Member and Board Transition

    MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. "As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka," said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. "Chris's expertise can bring tremendous value to the compan

    12/11/25 4:01:00 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Oruka Therapeutics Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/21/24 6:30:53 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/14/24 7:38:47 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/14/24 5:49:56 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care